BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim ’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy DesignationBI 425809, a novel glycine transporter-1 (Gly-T1) inhibitor to be Studied in First-of-its-Kind Phase III Trials, Incorporating Speech Analytics and Virtual Reality Functional Capacity Assessments.

Source: Boehringer Ingelheim Corporate News - May 24, 2021 Category: Research Source Type: news